Boston Scientific (NYSE:BSX) Releases FY 2025 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.870-2.940 for the period, compared to the consensus estimate of 2.860. The company issued revenue guidance of $19.3 billion-$19.6 billion, compared to the consensus revenue estimate of $19.1 billion. Boston Scientific also updated its Q2 2025 guidance to 0.710-0.730 EPS.

Analysts Set New Price Targets

A number of analysts recently issued reports on BSX shares. Piper Sandler upped their target price on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Robert W. Baird boosted their target price on Boston Scientific from $115.00 to $120.00 and gave the stock an “outperform” rating in a research report on Thursday. Citigroup raised their target price on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. UBS Group boosted their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, BTIG Research reaffirmed a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $114.22.

Boston Scientific Stock Performance

Boston Scientific stock opened at $101.13 on Friday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The company has a market capitalization of $149.58 billion, a price-to-earnings ratio of 80.90, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. Boston Scientific has a 12-month low of $70.97 and a 12-month high of $107.17. The firm’s fifty day moving average price is $98.75 and its 200 day moving average price is $94.69.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm had revenue of $4.66 billion for the quarter, compared to analysts’ expectations of $4.57 billion. On average, research analysts forecast that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 15,087 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total value of $1,585,191.09. Following the completion of the sale, the chief financial officer now directly owns 241,451 shares in the company, valued at $25,369,256.57. This represents a 5.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 138,009 shares of company stock worth $14,407,381. Company insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC lifted its holdings in Boston Scientific Co. (NYSE:BSX) by 0.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,376 shares of the medical equipment provider’s stock after buying an additional 226 shares during the period. Brighton Jones LLC’s holdings in Boston Scientific were worth $2,445,000 as of its most recent SEC filing. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.